Your session is about to expire
← Back to Search
Assistive Device
Abilitech Assist for Muscular Dystrophy
N/A
Recruiting
Research Sponsored by AbiliTech Medical Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up change from baseline before device intervention (30 days), and after device intervention (60 days)
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing a wearable device called the Abilitech Assist, which helps people with muscle problems move their arms. The study focuses on how well the device works in different settings, including safety and ease of use.
Eligible Conditions
- Muscular Dystrophy
- Acute Myeloid Leukemia
- Cerebral Palsy
- Muscular dystrophy
- Becker Muscular Dystrophy
- Facioscapulohumeral Muscular Dystrophy
- Duchenne Muscular Dystrophy
- Spinal Muscular Atrophy
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ change from baseline before device intervention (30 days), and after device intervention (60 days)
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change from baseline before device intervention (30 days), and after device intervention (60 days)
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Canadian Occupational Performance Measure (COPM)
Roll Evaluation of Activities of Life (REAL) assessment
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Abilitech AssistExperimental Treatment1 Intervention
The Abilitech™ Assist device is a passively powered orthotic device designed to support and assist the arms of patients with neuromuscular weakness for activities of daily living.
Find a Location
Who is running the clinical trial?
Richard M. Schulze Family FoundationUNKNOWN
AbiliTech Medical Inc.Lead Sponsor
2 Previous Clinical Trials
24 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger